ARTV
What one share of Artiva Biotherapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers.
Artiva Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.21 |
|---|---|
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$2.72 |
| Cash and investments | $6.17 |
| Book value | $7.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$35.78 | $4.06 | −$63.14 | — | −$201.83 |
| 2024 | $0.02 | −$5.81 | $0.06 | −$4.94 | — | — |
| 2025 | $0.00 | −$3.43 | $0.11 | −$3.25 | — | $4.45 |